SCHEMBL2575298

SCHEMBL2575298

CC(C(=O)O)c1c(O)noc1C[AsH2]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL68800 0.83
Bromide SCHEMBL7200266 0.82
SCHEMBL4437211 0.75 GRIA1 (0.36)
Aspartic Acid SCHEMBL5964784 0.67 GRIA1 (0.43)
SCHEMBL12481055 0.62 PTGS2 (0.32)
SCHEMBL30940446 0.60 TP53 (0.38)
SCHEMBL12648359 0.60 GRIA1 (0.49)
SCHEMBL5281708 0.60 GRIA1 (0.49)
SCHEMBL13319909 0.60 GRIA1 (0.41)
SCHEMBL5290687 0.60 GRIA1 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1978962-A2 COMPOSITIONS AND METHODS OF TREATMENT USING MODULATORS OF MOTONUERON DISEASES Kinemed, Inc. (US) 2008-10-15 EP claimed
WO-2007081910-A2 COMPOSITIONS AND METHODS OF TREATMENT USING MODULATORS OF MOTONUERON DISEASES KINEMED, INC. (US) 2007-07-19 WO claimed
EP-2382975-A2 Neurogenesis by modulating angiotensin Braincells, Inc. (US) 2011-11-02 EP disclosed